JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s - Fierce Biotech

Retrieved on: 2022-01-13 17:56:55

Tags for this article:

Click the tags to see associated articles and topics

JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s - Fierce Biotech. View article details on hiswai:

Excerpt

The biopharma went south last year when it canned a phase 3 asset, ziritaxestat, and ran into speed bumps with its JAK inhibitor, filgotinib, ...

Article found on: www.fiercebiotech.com